<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850381</url>
  </required_header>
  <id_info>
    <org_study_id>GBD 002</org_study_id>
    <nct_id>NCT01850381</nct_id>
  </id_info>
  <brief_title>Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease</brief_title>
  <acronym>GAP-PD</acronym>
  <official_title>GM 608 in A Phase IIA Pilot Double-blinded, Randomized, Placebo Controlled Trial in Mild to Moderate Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genervon Biopharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genervon Biopharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GM608 is an endogenous human embryonic stage neural regulatory and signaling peptide that
      controls the development, monitoring and correction of the human nervous system. The study
      drug is an oligopeptide with a sequence identical to one of the active sites of human
      Motoneuronotrophic Factor and is manufactured by solid phase synthesis. Preclinical research
      indicates it to be a neuro-protective agent in animal models of PD, other neuro-degenerative
      diseases and stroke. This trial is designed to test proof of principle, i.e. determine if a
      2-week treatment with this agent can restore the non-functioning nigral dopaminergic neurons
      in PD over a 3 month period, during which the placebo-treated arm is expected to have little
      or no worsening of the total UPDRS (Unified Parkinson's Disease Rating Scale)score compared
      to baseline.

      Study Objectives are:

        1. To compare the safety and tolerability of GM608 with placebo in a population of patients
           with early PD.

        2. To field test the study procedures for feasibility and efficiency

        3. To determine if there is any hint that injections of GM608 might slow the rate of
           clinical worsening of PD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background The investigational drug GM6028 is a synthetic oligopeptide containing 6 amino
      acids with a sequence identical to one of the active sites of human Motoneuronotrophic factor
      (MNTF), also referred to as GM6 in studies. MNTF is a novel human endogenous developmental
      stage neurotrophin for the nervous system with a specific human chromosome location.

      The investigators' preclinical animal study has shown that intravenously injected GM608 is
      able to penetrate the blood-brain barrier and enter the brain. GM608 has shown
      neuroprotection in a variety of in vitro and animal models of numerous CNS diseases including
      ischemic stroke, spinal cord injury, Parkinsons Disease (PD), ALS, MS, Alzheimer and
      Huntington Disease. In particular, the MPTP and 6-OHDA mouse model for PD all showed GM608
      has neuroprotective effect. GM608 also enhanced neuron cell survival very significantly in
      the CSF of patients with Huntington disease, MS, Stroke, Parkinson, Alzheimer and ALS.

      This pilot trial is designed to test proof of principle, i.e. determine if a 2-week treatment
      with this agent can restore the nonfunctioning nigral dopaminergic neurons in PD over a
      3month period, during which the placebo-treated arm is expected to have little or no
      worsening of the total UPDRS score compared to baseline. A Phase 1 Clinical Trial Study has
      been completed. The Phase 1 Trial primary objective is to determine the safety and
      tolerability and to establish the pharmacokinetic and pharmacodynamic properties of GM608 at
      0.5, 1.5, and 5.0 mg/kg administered as a single bolus intravenous dose in human subjects and
      after 3 consecutive daily doses of GM608 at the highest safe and tolerated dose of 5.0 mg/kg.
      The Phase 1 study established that 3 consecutive daily doses of 5.0 mg/kg of GM602 are safe
      and tolerated.

      Mechanism of Action Motoneuronotrophic factor (MNTF) is highly specific to the human nervous
      system. It is expressed rapidly during the first trimester of human fetal development,
      peaking at week nine. MNTF is a developmental stage regulatory (antisense) neuro-signaling
      molecule that binds perfectly on very specific receptors. Using In Silico Analysis, Genervon
      identified and developed as a drug candidate one of the active sites of MNTF, an analog of
      six amino acids named GM608.

      In the investigators' testing for efficacy in Parkinson disease MPTP and 6-OHDA animal
      models, GM608 demonstrated a dose dependent attenuation of PD in the mice with 20 mg/kg
      showing the most efficacious. Behavioral, biochemical and histological analysis demonstrated
      the attenuation illustrating a unique effect for GM608 in PD. These data suggest that GM608
      is effective in the mouse model of PD following IV injection and may be a potential treatment
      for PD patients.

      In the investigators' in vitro study in Parkinson disease, treatment with wortmannin (PI3K
      inhibitor) abrogated the protective effects of GM608 on SH-SY5Y cells which were subjected to
      salsolinol exposure for 24 hours. The results suggested that GM608 may function through the
      phosphatidylinositol 3-kinase (PI3K) pathway which is an important pathway in neuronal
      diseases.

      Although the neuroprotective mechanism in each of the animal studies is not well understood,
      the investigators hypothesize that GM608 respond to specific distress signal anywhere from
      the human nervous system through a common underlying mechanism by triggering specific
      pathway(s), possibly through the PI3 pathway and other pathways that protect neural tissues
      by increasing or decreasing specific gene(s) expressions.

      This is a single-center, prospective, randomized, double-blind, and placebo-controlled pilot
      study, involving 6 subjects not on any dopaminergic medication (i.e. levodopa or dopamine
      agonist). Subjects will be randomized 2:1 into one of two treatment arms: (1) 4 subjects will
      receive i.v. injections of GM608 and (2) 2 subjects will receive a matching placebo.
      Progression of clinical PD will be assessed using the UPDRS over 12 weeks. Safety and
      tolerability will also be compared between treated and placebo group.

      There will be 2 weeks of active treatment, followed by 10 weeks of assessment without active
      treatment. During the 2-week active treatment phase, each subject will receive one IV bolus
      injection once a day for three times a week during these 2 weeks for a total of six
      injections. Subjects will be evaluated by UPDRS at screening, at baseline, and the ends of
      weeks 2 (at visit 6 after dosing), 6, and 12. The study duration for each subject is 12
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from the mean total UPDRS score of the combined screening and baseline visits to the total UPDRS score at the Week-12 visit, comparing treated with placebo.Compare safety and tolerability with placebo.</measure>
    <time_frame>Baseline, week 2, week 6, week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in total UPDRS between the mean screening-baseline visits and end of Week 2 (at visit 6 after dosing), and week 6, comparing the two arms of the study encompassing the entire cohort of 6 subjects.</measure>
    <time_frame>Baseline, week 2, week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in UPDRS sub-scores (Mental, Activities of Daily Living, Motor) between the mean screening-baseline visits and ends of Week 2 (at visit 6 after dosing), 6, and 12, comparing the two arms of the study encompassing the entire cohort of 6 subjects.</measure>
    <time_frame>Baseline, week 2, week 6, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the development of sufficient disability to require a change in symptomatic therapy.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects requiring additional symptomatic treatment due to disability.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Schwab &amp; England ADL score from baseline to Week 2 (at visit 6 after dosing), 6, or 12.</measure>
    <time_frame>Baseline, week 2, week 6, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hoehn &amp; Yahr score (H&amp;Y), Beck Depression Inventory (BDI), and Montreal Cognitive Assessment (MOCA) scores from baseline to Week 2 (at visit 6 after dosing), 6, or 12.</measure>
    <time_frame>Baseline, week 2, week 6, week 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Secondary analyses will consider a comparison of slopes using a mixed-model approach with treatment as a fixed effect and subject-specific slopes as a random effect.</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>GM608</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 subjects will receive 320 mg of GM608. 6.4 mL of GM608 (50 mg/mL) will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 subjects will receive matching placebo (bacteriostatic saline). 6.4 mL Bacteriostatic saline will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM608</intervention_name>
    <description>For GM608: 320 mg/dose reconstituted with 6.4 mL bateriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.</description>
    <arm_group_label>GM608</arm_group_label>
    <other_name>GM602</other_name>
    <other_name>GM6</other_name>
    <other_name>GM604</other_name>
    <other_name>MNTF 6mer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.</description>
    <arm_group_label>Placebo comparator</arm_group_label>
    <other_name>Bacteriostatic saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  with mild-moderate idiopathic PD diagnosed based on UK PD Brain Bank criteria.

          -  Age &gt; 30

          -  Motor UPDRS Score â‰¥ 15

          -  Hoehn &amp; Yahr stage &lt;3

          -  Diagnosis of PD &lt;10 years

          -  Have fully completed informed consent form

          -  May be on antiparkinsonian medications of an MAO-B inhibitor, an anticholinergic, or
             amantadine, but not levodopa or dopamine agonist

        Exclusion Criteria:

          -  Patients with atypical parkinsonism (such as suspected PSP, MSA or CBD) and secondary
             parkinsonism (such as NPH, drug-induced, or vascular parkinsonism).

          -  Patients with uncertainty as to having classical Parkinson disease, such as those who
             might have scans without evidence of dopaminergic deficit (SWEDDs)

          -  Patients not willing to give an informed consent

          -  Patients who are on a dopaminergic medication (levodopa or dopamine agonist)

          -  Presence of a medical or psychiatric comorbidity that can compromise participation in
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley Fahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University Medical Center/NY Presbyterian Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center/NY Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2013</study_first_submitted>
  <study_first_submitted_qc>May 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <disposition_first_submitted>August 1, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>August 2, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 8, 2017</disposition_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Phase 2A</keyword>
  <keyword>Pilot trial</keyword>
  <keyword>human Motoneuronotrophic Factor</keyword>
  <keyword>neuroprotective agent</keyword>
  <keyword>neurodegenerative diseases</keyword>
  <keyword>rate of clinical progression of PD</keyword>
  <keyword>UPDRS</keyword>
  <keyword>Proof of principle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

